Is Corcept Therapeutics Incorporated's (NASDAQ:CORT) Recent Stock Performance Tethered To Its Strong Fundamentals?
Is Corcept Therapeutics Incorporated's (NASDAQ:CORT) Recent Stock Performance Tethered To Its Strong Fundamentals?
Most readers would already be aware that Corcept Therapeutics' (NASDAQ:CORT) stock increased significantly by 35% over the past three months. Given that the market rewards strong financials in the long-term, we wonder if that is the case in this instance. In this article, we decided to focus on Corcept Therapeutics' ROE.
大多数读者已经知道Corcept Therapeutics (纳斯达克:CORT)的股票在过去三个月里大幅增长了35%。由于市场对长期强劲的财务状况进行奖励,我们想知道这种情况是否成立。在本文中,我们决定关注Corcept Therapeutics的ROE。
Return on equity or ROE is a key measure used to assess how efficiently a company's management is utilizing the company's capital. Simply put, it is used to assess the profitability of a company in relation to its equity capital.
股本回报率或ROE是一项用于评估公司管理层如何利用公司资本的效率的关键指标。简而言之,它用于评估公司相对于其股本资本的盈利能力。
How Do You Calculate Return On Equity?
怎样计算ROE?
Return on equity can be calculated by using the formula:
股东权益报酬率可以使用以下公式计算:
Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity
净资产收益率 = 净利润(从持续经营中获得)÷ 股东权益
So, based on the above formula, the ROE for Corcept Therapeutics is:
所以,根据上述公式,Corcept Therapeutics的ROE为:
22% = US$118m ÷ US$548m (Based on the trailing twelve months to March 2024).
22% = 11800万美元 ÷ 54800万美元 (基于过去12个月到2024年3月)。
The 'return' is the yearly profit. Another way to think of that is that for every $1 worth of equity, the company was able to earn $0.22 in profit.
“收益”是年收益。换句话说,对于每一美元的净资产,公司能够获得0.22美元的净利润。
What Has ROE Got To Do With Earnings Growth?
ROE与盈利增长有什么关系?
So far, we've learned that ROE is a measure of a company's profitability. Based on how much of its profits the company chooses to reinvest or "retain", we are then able to evaluate a company's future ability to generate profits. Assuming all else is equal, companies that have both a higher return on equity and higher profit retention are usually the ones that have a higher growth rate when compared to companies that don't have the same features.
到目前为止,我们已经了解到roe是衡量公司盈利能力的一种指标。根据公司选择重新投资或'保留'多少利润,我们就能够评估公司未来生成利润的能力。假设其他条件相同,那些具有更高股本回报率和更高利润留存的公司通常比没有这些特征的公司有更高的增长率。
Corcept Therapeutics' Earnings Growth And 22% ROE
Corcept Therapeutics的盈利增长和22%的ROE
To start with, Corcept Therapeutics' ROE looks acceptable. And on comparing with the industry, we found that the the average industry ROE is similar at 22%. Despite the moderate return on equity, Corcept Therapeutics has posted a net income growth of 3.3% over the past five years. A few likely reasons that could be keeping earnings growth low are - the company has a high payout ratio or the business has allocated capital poorly, for instance.
首先,Corcept Therapeutics的ROE看起来可接受。与行业相比,我们发现平均行业ROE也是22%。尽管净资产回报率适中,但Corcept Therapeutics在过去五年中的净利润增长率为3.3%。可能使盈利增长低的原因有很多,例如公司的支付比率很高或业务分配资本不善等。
As a next step, we compared Corcept Therapeutics' net income growth with the industry, and pleasingly, we found that the growth seen by the company is higher than the average industry growth of 0.03%.
接下来,我们将Corcept Therapeutics的净利润增长与行业进行比较,令人高兴的是,我们发现公司的增长率高于行业平均增长率的0.03%。
![big](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240716/0-5bac5548028c2f714a0c0687d9a9d209-0-6b5b6260d18ffcfa85d6be9453d35a60.png/big)
Earnings growth is a huge factor in stock valuation. It's important for an investor to know whether the market has priced in the company's expected earnings growth (or decline). Doing so will help them establish if the stock's future looks promising or ominous. One good indicator of expected earnings growth is the P/E ratio which determines the price the market is willing to pay for a stock based on its earnings prospects. So, you may want to check if Corcept Therapeutics is trading on a high P/E or a low P/E, relative to its industry.
盈利增长是股票估值的一个重要因素。对于投资者来说,了解市场是否已经计入了公司预期的盈利增长(或下降)是很重要的。 这样做将帮助他们确定该股票的前景究竟是好还是坏。了解一个很好的预期盈利增长指标是P/E比率,它确定了市场愿意根据其盈利前景为一个股票支付的价格。因此,您可能需要检查Corcept Therapeutics的P/E比率是高于还是低于其行业。
Is Corcept Therapeutics Making Efficient Use Of Its Profits?
Corcept Therapeutics是否充分利用其利润?
Corcept Therapeutics doesn't pay any regular dividends, meaning that potentially all of its profits are being reinvested in the business. However, there's only been very little earnings growth to show for it. So there might be other factors at play here which could potentially be hampering growth. For example, the business has faced some headwinds.
Corcept Therapeutics不支付任何定期分红,这意味着其所有利润都可能被再投资到业务中。但由此产生的收益增长却非常微小。因此,可能存在其他因素影响了其增长。例如,该企业面临了一些阻力。
Conclusion
结论
Overall, we are quite pleased with Corcept Therapeutics' performance. Particularly, we like that the company is reinvesting heavily into its business, and at a high rate of return. Unsurprisingly, this has led to an impressive earnings growth. Having said that, looking at the current analyst estimates, we found that the company's earnings are expected to gain momentum. To know more about the company's future earnings growth forecasts take a look at this free report on analyst forecasts for the company to find out more.
总的来说,我们对Corcept Therapeutics的表现非常满意。特别是,我们喜欢该公司积极重投其业务并获得高回报率的情况。不出所料,这导致了出色的盈利增长。话虽如此,在查看当前的分析师预测时,我们发现该公司的收益预计将获得动力。如果想了解更多关于该公司未来盈利增长预测的信息,请查看有关该公司的分析师预测的免费报告。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有反馈?对内容感到担忧?请直接与我们联系。或者,发送电子邮件至editorial-team (at) simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
对本文有反馈?对内容感到担忧?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。